Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00095277 |
Recruitment Status
:
Completed
First Posted
: November 3, 2004
Last Update Posted
: March 13, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anemia | Drug: Darbepoetin Alfa | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 220 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer |
Study Start Date : | October 2004 |

- To demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to darbepoetin alfa once every 4 weeks.
- Assess efficacy
- Assess PROs
- Assess relationship between PROs and hemoglobin concentration
- Assess safety of dose and frequency

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00095277
Study Director: | MD | Amgen |
Additional Information:
Publications of Results:
Responsible Party: | Global Development Leader, Amgen Inc. |
ClinicalTrials.gov Identifier: | NCT00095277 History of Changes |
Other Study ID Numbers: |
20030204 |
First Posted: | November 3, 2004 Key Record Dates |
Last Update Posted: | March 13, 2009 |
Last Verified: | March 2009 |
Keywords provided by Amgen:
non-myeloid malignancies myeloma Anemia of Cancer |
Additional relevant MeSH terms:
Anemia Hematologic Diseases Darbepoetin alfa Hematinics |